CMMB
Chemomab Therapeutics Ltd. NASDAQ Listed Feb 12, 2019$1.59
Pre-mkt
$1.60
+0.95%
Mkt Cap $10.1M
52w Low $1.44
4.5% of range
52w High $4.76
50d MA $1.69
200d MA $2.08
P/E (TTM)
—
EV/EBITDA
—
P/B
0.8x
Debt/Equity
0.0x
ROE
-72.9%
P/FCF
-0.9x
RSI (14)
36.80
ATR (14)
$0.14
Beta
0.58
50d MA
$1.69
200d MA
$2.08
Avg Volume
46.1K
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Building 7 · Tel Aviv 6158002 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.20 | -0.24 | -20.0% | 1.93 | -1.6% | -7.8% | -5.6% | -6.5% | +1.3% | -2.5% | — |
| Nov 13, 2025 | AMC | -0.20 | -0.80 | -300.0% | 2.55 | -1.2% | +4.3% | -2.3% | +5.0% | -1.1% | -10.0% | — |
| Aug 14, 2025 | AMC | -0.80 | -0.36 | +55.0% | 3.59 | +0.8% | +3.6% | +1.1% | -1.1% | -1.3% | -3.5% | — |
| May 15, 2025 | AMC | -0.20 | -0.14 | +30.0% | 5.16 | +0.0% | +6.2% | +1.5% | +0.0% | -0.7% | -1.4% | — |
| Mar 3, 2025 | AMC | -0.20 | -0.16 | +20.0% | 6.04 | -5.3% | -13.9% | +7.7% | +5.7% | -15.5% | +4.0% | — |
| Nov 14, 2024 | AMC | -0.20 | -0.20 | +0.0% | 6.96 | -2.9% | -4.0% | -1.2% | -1.8% | +1.2% | -2.4% | — |
| Aug 21, 2024 | AMC | -0.20 | -0.26 | -30.0% | 4.88 | -2.5% | +0.0% | +14.8% | +12.9% | +4.4% | +12.7% | — |
| May 9, 2024 | AMC | -0.20 | -0.28 | -40.0% | 3.24 | -2.5% | +3.7% | -3.0% | +8.0% | -0.9% | -0.3% | — |
| Mar 7, 2024 | AMC | -0.40 | -0.26 | +35.0% | 3.20 | -5.9% | -3.1% | +6.5% | +4.2% | -4.1% | +0.6% | — |
| Nov 9, 2023 | AMC | -0.60 | -0.34 | +43.3% | 2.40 | -0.8% | -1.7% | -6.8% | +10.9% | +34.0% | -19.3% | — |
| Aug 14, 2023 | AMC | -0.80 | -0.72 | +10.0% | 4.52 | -6.2% | -0.9% | -4.5% | -1.9% | +3.8% | +0.0% | — |
| May 11, 2023 | AMC | -0.80 | -0.80 | +0.0% | 6.48 | +1.2% | -2.5% | +3.2% | +1.2% | +9.1% | +2.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.40 | $3.40 | +0.0% | +2.4% | -2.0% | -7.9% | -1.3% | -2.6% |
| May 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.16 | $5.16 | +0.0% | +6.2% | +1.5% | +0.0% | -0.7% | -1.4% |
| Feb 20 | Maxim Group | Maintains | Buy → Buy | — | $7.60 | $7.28 | -4.2% | -6.8% | -3.4% | -1.8% | -7.7% | +5.2% |
| Nov 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.96 | $6.76 | -2.9% | -4.0% | -1.2% | -1.8% | +1.2% | -2.4% |
| May 6 | Oppenheimer | Upgrade | Perform → Outperform | — | $2.96 | $3.28 | +10.8% | +15.2% | +4.4% | -18.5% | +11.7% | +3.7% |
| Mar 8 | Oppenheimer | Maintains | Perform → Perform | — | $3.20 | $3.01 | -5.9% | -3.1% | +6.5% | +4.2% | -4.1% | +0.6% |
| Jun 7 | Oppenheimer | Downgrade | Outperform → Perform | — | $6.88 | $6.88 | +0.0% | -1.2% | +2.9% | +0.0% | -1.1% | +2.3% |
| Apr 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.52 | $6.52 | +0.0% | +1.8% | +1.2% | -6.0% | +2.5% | -3.7% |
| Mar 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.16 | $16.36 | +7.9% | +7.9% | +2.7% | -5.5% | +0.0% | +5.5% |
| Dec 7 | Aegis Capital | Maintains | Buy → Buy | — | $29.72 | $31.76 | +6.9% | +6.2% | +2.8% | -1.1% | -0.4% | -1.4% |
| May 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $64.28 | $67.08 | +4.4% | +4.9% | +0.9% | +4.0% | -3.6% | +2.1% |
| May 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $79.40 | $92.00 | +15.9% | -0.1% | -4.6% | -5.0% | -4.6% | -3.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | Mor George AdiDir/Off | Chief Executive Officer | Buy | 4,926 | $2.08 | $10K | 139,131 | -6.45% | +2.25% |
| May 29, 2026 | Mor George AdiDir/Off | Chief Executive Officer | Buy | 4,878 | $2.05 | $10K | 134,205 | -6.45% | +2.25% |
No recent filings available.
Institutional (13F) — Top 10
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Adar1 Capital Management, Llc | 80,000 | $126K | New | Mar 2026 |
| 2 | Citadel Advisors Llc | 64,182 | $101K | Reduced | Mar 2026 |
| 3 | Kestra Private Wealth Services, Llc | 61,710 | $97K | Added | Mar 2026 |
| 4 | Jane Street Group, Llc | 15,598 | $26K | Reduced | Dec 2025 |
| 5 | Susquehanna International Group, Llp | 13,491 | $21K | New | Mar 2026 |
| 6 | Bnp Paribas Financial Markets | 8,425 | $13K | Added | Mar 2026 |
| 7 | Morgan Stanley | 7,550 | $12K | Reduced | Dec 2025 |
| 8 | Gamma Investing Llc | 7,579 | $12K | Added | Mar 2026 |
| 9 | Ubs Group Ag | 8 | $13 | Reduced | Mar 2026 |
| 10 | Northwestern Mutual Wealth Management Co | 2 | $3 | New | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$10.1M
Enterprise Value
-$225K
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.02x
P/B
0.82x
P/S
—
P/FCF
-0.90x
EV/EBITDA
—
Shares Out
6.4M
Financials (TTM)
Revenue
$0
Net Income
-$7.5M
EBITDA
-$7.9M
Free Cash Flow
-$11.2M
Op Cash Flow
-$11.2M
EPS Basic
$-1.42
EPS Diluted
$-1.10
EPS Forward
$-0.02
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$13.8M
Total Liab.
$1.5M
Total Equity
$12.3M
Cash
$10.4M
LT Debt
$0
Book Value/Sh
$1.93
Debt/Equity
0.00x
Current Ratio
9.08
Quick Ratio
9.08
Returns & Growth
ROE
-72.9%
ROA
-65.1%
ROIC
-78.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
+54.5%
Price Returns
2W
-10.7%
1M
+36.1%
3M
+7.5%
6M
-23.7%
12M
-62.1%
Technicals
52W High
$4.76
52W Low
$1.44
50d MA
$1.69
200d MA
$2.08
RSI (14)
36.80
ATR (14)
$0.14
Beta
0.58
Avg Volume
46K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 10:11am
· Source: financialmodelingprep.com